NCT02527746 2024-02-23
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 1 Completed
EVIVE Biotechnology
Institut de cancérologie Strasbourg Europe
TTY Biopharm
GBG Forschungs GmbH
GBG Forschungs GmbH
Shandong Cancer Hospital and Institute
King Faisal Specialist Hospital & Research Center